Series B

A health plan reports 13% lower costs and 90% satisfaction by integrating care, not just insuring it. Can this model fix employer healthcare?

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

As it nears $10B in assets, investment firm Disruptive hires a top tech advisor, signaling a new phase of strategic growth for its unique investment model.

Forethought founder Deon Nicholas unveils Espa, an AI executive assistant that executes tasks, aiming to democratize productivity for all.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

Three industry titans launch AlphaDrive, a $100M fund blending VC and private equity to back the next generation of Israeli Cyber-AI startups.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

UTime's latest capital raise is a fraction of its needs. We dive into the firm's mounting losses, stock dilution, and what this means for its future.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

AI-native firm Norm Law adds veteran tax and fund formation counsel, deepening its tech-driven challenge to the traditional legal services model for investors.

A new AI platform promises to fix billions in revenue loss from complex cardiac coding, but will it empower or replace human experts in the process?

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

A new device gets the CE Mark to modernize a 60-year-old cardiac test, promising clearer, faster diagnosis of shunts linked to stroke in millions.

Raising $100M led by Sequoia, Parallel Web Systems is building the critical infrastructure for AI agents, reshaping how industries access the internet.

A $10T wave of business sales is coming. A new partnership aims to de-risk these deals for everyday entrepreneurs with insurance once reserved for Wall Street.

Ostium's new decentralized execution layer leverages institutional partners like Jump to offer a transparent, on-chain alternative to the $10T CFD market.

AI Council 2026 reveals the industry's next chapter: European founders are flocking to SF, engineering is being reinvented, and video is set to break everything.

After a $700M exit with Peakon and leading a space-tech venture, serial entrepreneur Phil Chambers brings deep operational expertise to Balderton.